MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Betrixaban

CAS No. : 330942-05-7

MCE 国际站：Betrixaban

产品活性：Betrixaban (PRT054021) 是一种有效的，具有口服活性的选择性 factor Xa (fXa) 抑制剂，IC₅₀ 为 1.5 nM。Betrixaban 具有抗血栓形成效果。

研究领域：Metabolic Enzyme/Protease

作用靶点：Factor Xa

In Vitro: Betrixaban (PRT054021) shows IC₅₀ of 8.9 μM in patch clamp hERG assays.
Betrixaban shows an IC₅₀ and a K_i of 6.3 μM and 3.5 μM for the plasma kallikrein, respectively.
Betrixaban (hERG K_i 1.8 μM) exhibits significantly lower hERG activity than all the others (hERG K_i⩽0.5 μM).
Betrixaban (5-25 ng/mL) inhibits thrombin generation.

In Vivo: Betrixaban (0.5 mg/kg, i.v.; 2.5 mg/kg, p.o.) has oral bioavailability of 51.6% in dog.
Betrixaban (0.75 mg/kg, i.v.; 7.5 mg/kg, p.o.) has oral bioavailability of 58.7% in monkey.
Betrixaban mediated whole-blood INR increase is reversed by r-Antidote. After i.v. infusion for 30 min, the total plasma concentrations of Betrixaban is 0.2±0.01 μM, and the percentages of unbound inhibitor is 40%±7.2%. After administration of r-Antidote, the total plasma concentration increased to 2.0±0.4 μM, and the percentage of unbound inhibitor declined to 0.3%±0.1%.
Betrixaban (3 mg/kg) shows nearly comparable inhibition of thrombus mass to enoxaparin 1.6 mg/kg (76% vs 96% inhibition) in the rabbit abdominal vena cava model of clot accretion on cotton threads.
Betrixaban (19.1 mg/kg) is at least as effective at maintaining patency as enoxaparin 7.6 mg/kg and clopidogrel 3 mg/kg/d (90% vs 70% vs 80% patency, respectively) in the ferric chloride injury model of rodent carotid artery.

相关产品：Drug Repurposing Compound Library Plus  |  FDA-Approved Drug Library Plus  |  FDA-Approved Drug Library Mini  |  Bioactive Compound Library Plus  |  Metabolism/Protease Compound Library  |  FDA-Approved Drug Library  |  Drug Repurposing Compound Library  |  Anti-Cardiovascular Disease Compound Library  |  Anti-COVID-19 Compound Library  |  Orally Active Compound Library  |  FDA Approved & Pharmacopeial Drug Library  |  Drug-Induced Liver Injury (DILI) Compound Library  |  Children’s Drug Library  |  Human Metabolite Library  |  Coagulation and Anti-coagulation Compound Library  |  Heterocyclic Compound Library  |  Off-patent Drug Library  |  Highly Selective Inhibitors Library  |  Edoxaban tosylate  |  Delparantag  |  BMS-262084  |  5-R-Rivaroxaban  |  Edoxaban-d₆  |  Methoxycarbonyl-D-Nle-Gly-Arg-pNA  |  FXIa-IN-9  |  Gabexate mesylate  |  Betrixaban hydrochloride  |  Abelacimab  |  RWJ-445167  |  Fondaparinux sodium  |  Heparin sodium salt (MW 15kDa)  |  ARC19499  |  BMS-654457  |  FXIa-IN-6  |  Boc-Ile-Glu-Gly-Arg-AMC  |  Osocimab  |  FXIa-IN-13  |  EMD 495235  |  Bismuth subgallate  |  Asundexian  |  FXIa-IN-1  |  LY-517717  |  Apixaban  |  Rivaroxaban

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物  |  寡核苷酸  |  抗体  |  点击化学

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿最全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种顶级期刊及制药专利收录了MCE客户的科研成果；
•   专业团队跟踪最新的制药及生命科学研究进展，为您提供全球最新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。